We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Impact of Cryopreserved Placental Allografts on Biochemical Recurrence in Prostate Cancer.
- Authors
Gottlieb, Josh; Hanes, Douglas A.; Bustos, Matias A.; Choe, Jane; Luu, Albert; Seizer, Daniel; Hoon, Dave S. B.; Wilson, Timothy G.
- Abstract
Simple Summary: Placental allograft tissue has been extensively used in wound healing. It can also be placed along the neurovascular bundles during radical prostatectomy to improve post-operative continence and erectile function recovery. The existing literature shows how placental allografts lead to improved functional recovery after radical prostatectomy. It is unknown whether these allografts have an impact on biochemical recurrence (BCR). Our study was a single surgeon retrospective review of 362 radical prostatectomy cases. The subgroups were the negative control group and two brands of cryopreserved amniotic membrane (CAM). Our data show improved continence recovery using CAM allografts. At a median follow-up of 41 months, there was no observed impact of BCR. Interestingly, in vitro analysis also revealed decreased cell viability of prostate cancer cell lines when incubated with the CAM allograft. Although further investigation is required, our data do not support a need for oncologic concern while using CAM allografts during radical prostatectomy. Background: Human placental allografts are widely used to promote wound healing. Placental (or amniotic membrane/umbilical cord) allografts are placed along the neurovascular bundles during radical prostatectomy to improve continence and erectile function recovery. It is unknown whether placental allografts impact biochemical recurrence (BCR). Methods: This was a single-surgeon retrospective study of 566 robotic radical prostatectomies performed from April 2015 to March 2021. The patients were divided into three groups: the negative control, Brand A, and Brand B. Brand A and Brand B were both cryopreserved amniotic membrane (CAM) allografts. A total of 324 cases were included for BCR Kaplan–Meier and risk-adjusted multivariate analyses (362 for continence analysis). In vitro analyses were performed to determine the effect of CAM allografts on prostate cancer (PCa) cell line growth. Results: For propensity score-matched analysis (adjusting for pre-operative PSA, tumor stage, Gleason Grade, and margin status), (1) the allograft groups did not show differences in time to BCR vs. the negative control group (p = 0.7), and (2) combined allograft treatment groups showed better continence recovery vs. the negative controls (p = 0.01). In vitro, placental allografts reduced PCa cell line growth in co-culture assays. Conclusions: cryopreserved AM allografts (combined or individual brands) did not show a significant effect on BCR but improved continence recovery for PCa patients.
- Subjects
PLACENTA; SURGICAL robots; CRYOPRESERVATION of organs, tissues, etc.; CANCER relapse; RESEARCH funding; URINARY incontinence; RADICAL prostatectomy; PROSTATE tumors; HOMOGRAFTS; TREATMENT effectiveness; RETROSPECTIVE studies; DESCRIPTIVE statistics; CELL lines; FETAL membranes; IMPOTENCE; MEDICAL records; ACQUISITION of data; PROGRESSION-free survival; DATA analysis software
- Publication
Cancers, 2024, Vol 16, Issue 17, p2973
- ISSN
2072-6694
- Publication type
Article
- DOI
10.3390/cancers16172973